Alcon Focuses On Non-Medicare Market For AcrySof ReStor Intraocular Lens

Alcon initially will target the 10%-20% of U.S. patients that undergo an intraocular lens procedure outside of the Medicare system for its newly-approved AcrySof ReStor accommodating IOL